Can Angiodynamics Level the PICC Playing Field?

Angiodynamics is still trying to level the competitive playing field for its peripherally inserted central catheters (PICCs). "We continue to believe that if our PICCs are able to compete on  a level playing field, we can gain share in this market, particularly given the gains we have seen from our BioFlow Midline ports and dialysis product families," said Jim Clemmer, the company's president and CEO, during Angiodynamics' most recent earnings call. According to SeekingAlpha transcripts of the call, its lawsuit against C.R. Bard is "moving forward as planned." Hear industry luminaries share their insights at the MD&M West conference, February 6-8, 2018, in Anaheim, CA. Use promo code "MDDI" for 20% off conference registration and free expo access.   The Albany, NY-based company filed the suit last May, accusing Bard of violating federal antitrust laws by tying the sale of its tip confirmation system to its own line of PICCs. This puts Angiodynamics at a competitive disadvantage, the company said, because customers who want to buy Bard's tip location system must also buy Bard's PICCs. Angiodynamics sells the BioFlo PICCs, and claims they are superior. Tip location systems are designed to aid clinicians in the bedside placement of a PICC. With regard to timing of the lawsuit, Steve Trowbridge, a senior vice president and general counsel at Angiodynamics, said timing on any litigation is very hard to predict, and the company is in the "very early stages" of some of the m...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Medical Device Business Source Type: news